67 related articles for article (PubMed ID: 38660023)
1. Epidermal growth factor receptor-targeted sonoporation with microbubbles enhances therapeutic efficacy in a squamous cell carcinoma model.
Hirabayashi F; Iwanaga K; Okinaga T; Takahashi O; Ariyoshi W; Suzuki R; Sugii M; Maruyama K; Tominaga K; Nishihara T
PLoS One; 2017; 12(9):e0185293. PubMed ID: 28938010
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor.
Taniguchi Y; Kawano K; Minowa T; Sugino T; Shimojo Y; Maitani Y
Cancer Sci; 2010 Oct; 101(10):2207-13. PubMed ID: 20608940
[TBL] [Abstract][Full Text] [Related]
3. PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals.
Kim JY; Shin JH; Kim MJ; Choi B; Kang Y; Choi J; Kim SH; Kwan D; Kim DH; Chun E; Lee KY
Biomark Res; 2024 May; 12(1):52. PubMed ID: 38816856
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
Bioorg Chem; 2024 May; 149():107500. PubMed ID: 38823310
[TBL] [Abstract][Full Text] [Related]
5. Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting.
Obaid G; Samkoe K; Tichauer K; Bano S; Park Y; Silber Z; Hodge S; Callaghan S; Guirguis M; Mallidi S; Pogue B; Hasan T
Nano Res; 2021 May; 14(5):1344-1354. PubMed ID: 33717420
[TBL] [Abstract][Full Text] [Related]
6. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
8. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
[TBL] [Abstract][Full Text] [Related]
9. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
[TBL] [Abstract][Full Text] [Related]
10. Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.
Chang DK; Li PC; Lu RM; Jane WN; Wu HC
PLoS One; 2013; 8(12):e83239. PubMed ID: 24386166
[TBL] [Abstract][Full Text] [Related]
11. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature.
Sasaki A; Fujimoto Y; Inada T; Ishizuka A; Ehara J; Ogita S; Norisue Y
J Med Case Rep; 2023 Sep; 17(1):410. PubMed ID: 37759318
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
